摘要
目的总结性探讨分析阿替普酶、重组链激酶在ST段抬高型心肌梗死中的治疗效果。方法 100例ST段抬高型心肌梗死患者,随机分为观察组和对照组,各50例。观察组患者采取阿替普酶治疗,对照组患者采取重组链激酶溶栓治疗,对两组患者的血管再通率、出血率、并发症发生率进行对比分析。结果观察组患者治疗后的60、90 min血管再通率分别为66.00%、84.00%,均高于对照组的20.00%、44.00%,差异有统计学意义(P<0.05)。观察组的出血率为26.00%,低于对照组的60.00%,观察组的并发症发生率为6.00%,低于对照组的34.00%,差异均有统计学意义(P<0.05)。结论 ST段抬高型心肌梗死患者选择阿替普酶、重组链激酶溶栓时,阿替普酶可以提高血管再通率,降低出血率和并发症发生率,值得在临床工作中加大阿替普酶的推广力度。
Objective To explore and analyze the treatment effect of alteplase and recombinant streptokinase for the treatment of ST-segment elevation myocardial infarction. Methods A total of 100 STsegment elevation myocardial infarction patients were randomly divided into observation group and control group,with 50 cases in each group. The observation group received alteplase for treatment, and the the control group received recombinant streptokinase thrombolysis for treatment. Comparison and analysis on vessel repass rate,bleeding rate and incidence of complications in two groups. Results The observation group had vessel repass rate after 60 and 90 min of treatment respectively as 66.00% and 84.00%, which were all higher than 20.00% and 44.00% in the control group, and the difference had statistical significance (P<0.05). The observation group had lower bleeding rate as 26.00% than 60.00% in the control group, and lower incidence of complications as 6.00% than 34.00% in the control group. All their differences had statistical significance (P<0.05). Conclusion For ST-segment elevation myocardial infarction patients treated with alteplase and recombinant streptokinase thrombolysis, alteplase can improve vessel repass rate and reduce bleeding rate and incidence of complications. So it is worth to strengthen the promotion of alteplase in clinical work.
作者
卢冬
LU Dong(Shenyang Emergency Center, Shenyang 110000, China)
出处
《中国现代药物应用》
2017年第5期60-62,共3页
Chinese Journal of Modern Drug Application
关键词
阿替普酶
重组链激酶
心肌梗死
Alteplase
Recombinant streptokinase
Myocardial infarction
